| Expression pattern: |
DN |
| Associated gene: |
HBEGF, COL1A1, alpha-SMA, HAS1, HAS2, SMAD2/3, DYM |
| Associated microRNA: |
miR-383-3p |
| Biological function: |
circ-0007006 suppresses fibrotic activation of orbital fibroblasts, reduces fibrotic marker expression, inhibits SMAD2/3 phosphorylation and cell proliferation, and increases apoptosis in the context of type II TAO fibrosis. |
| Molecular mechanism: |
ceRNA mechanism: circ-0007006 acts as a sponge for miR-383-3p, alleviating miR-383-3p-mediated repression of HBEGF and stabilizing HBEGF expression; it also suppresses TGF-beta/SMAD2/3 phosphorylation-associated fibrosis. |
| Biological pathway or process: |
fibrosis (inhibits); TGF-beta/SMAD (inhibits); proliferation (inhibits); apoptosis (promotes); ceRNA regulation (other); mRNA stability (promotes); cell cycle (other); other pathway/process (other) |
| Detected method: |
Q
S
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; circRNA-seq; RT-qPCR; FISH / smFISH; IHC (Immunohistochemistry); IF (Immunofluorescence); RNA Pull-Down; Luciferase Reporter Assay; Transfection; MTT; Western Blot; Clinical Sample Validation; Bioinformatics Analysis |
| Clinical significance: |
circ-0007006 is proposed as a potential therapeutic target for fibrotic type II TAO and may have potential diagnostic and subtype differentiation value. |
| Description: |
hsa_circ_0007006 is downregulated in fibrotic type II TAO tissues. In orbital fibroblasts, circ-0007006 attenuates fibrotic activation by suppressing ECM/fibrotic markers and SMAD2/3 phosphorylation, while reducing proliferation and increasing apoptosis. Mechanistically, it functions as a ceRNA for miR-383-3p to stabilize HBEGF expression, forming the circ-0007006/miR-383-3p/HBEGF anti-fibrotic axis with potential therapeutic value. |
| Confidence score: |
0.8598 |